Calcium + Vitamin D3

Calcium + Vitamin D3 is a nutritional supplement that plays an important role in preventing osteoporosis and other bone-related diseases. Calcium, magnesium, and vitamin D3 are the macronutrients for bone health. Very little calcium is absorbed without vitamin D3. Like calcium, magnesium increases bone strength and rigidity.

Each film-coated tablet contains: Calcium Carbonate USP 1500 mg (equivalent to 600 mg elemental Calcium), Cholecalciferol BP 2 mg (equivalent to 200 IU Vitamin D3), Magnesium Oxide USP 66.34 mg (equivalent to 40 mg Magnesium), Zinc Oxide USP 9.34 mg (equivalent to 7.5 mg Zinc), Cupric Oxide 1.25 mg (equivalent to 1 mg Copper), Manganese Sulfate Monohydrate 5.54 mg (equivalent to 1.8 mg Manganese), and Boron Citrate 5 mg (equivalent to 0.25 mg Boron).

• Prevention and treatment of osteoporosis
• To maintain strong bone growth
• Proper functioning of heart, muscle and nerves
• Nutritional supplement
• Bone development and regeneration of bone
• Pregnancy & lactation
• Deficiency of Calcium, Vitamin D3, Magnesium, Zinc, Copper, Manganese & Boron

Adults: 1 film-coated tablet twice daily, preferably 1 tablet in the morning and 1 tablet in the evening, with or just after main meals with a full glass of water, or as directed by a physician.

Children (3-7 years): 1 effervescent tablet daily.

Children (7 years and older): 1 to 2 effervescent tablets daily.

Note: Allowances should be made for calcium and vitamin D3 supplements from other sources.

Common side effects: Mild gastrointestinal disturbances such as constipation, flatulence, nausea, gastric pain, diarrhea (rare).

Occasional skin rash has been reported with vitamin D3 supplements.

Hypercalciuria and, in rare cases, hypercalcemia have been seen with long-term treatment at high doses.

• Patients with mild to moderate renal failure or mild hypercalciuria should be supervised carefully.
• Periodic checks of plasma calcium levels and urinary calcium excretion should be made.
• In patients with a history of renal stones, urinary calcium excretion should be measured to exclude hypercalciuria.
• With long-term treatment, monitor serum and urinary calcium levels and kidney function; reduce or stop treatment temporarily if urinary calcium exceeds 7.5 mmol/24 hours.
• Allowances should be made for calcium and vitamin D3 supplements from other sources.

• Hypercalcemia resulting from myeloma, bone metastasis or other malignant bone disease, sarcoidosis, primary hyperparathyroidism, and vitamin D3 overdosage
• Severe renal failure
• Hypersensitivity to any of the ingredients
• Relative contraindications: osteoporosis due to prolonged immobilization, renal stones, severe hypercalciuria

• Thiazide diuretics: Reduce urinary calcium excretion, increasing risk of hypercalcemia.
• Digitalized patients (cardiac glycosides): Hypocalcemia must be avoided; calcium combination may attenuate cardiac glycoside effects.
• Foods containing oxalic acid, phosphate, or phytic acid: May reduce calcium absorption.
• Phenytoin or barbiturates: May decrease vitamin D3 effect due to metabolic activation.
• Glucocorticoids: May decrease vitamin D3 effect.
• Thyroxine, bisphosphonates, sodium fluoride, quinolone or tetracycline antibiotics, iron: Calcium salts may reduce absorption; allow at least 4 hours interval.